Source: Politico Europe
Introduction
Europe currently finds itself at a critical juncture regarding its standing in the global pharmaceutical landscape. While the region was once the undisputed pioneer of medical breakthroughs that improved countless lives, the reality is that Europe cannot afford to lose the race for biomedical innovation.
The continent is now struggling to maintain its competitive edge against dominant international players. With the United States utilizing aggressive trade strategies and China rapidly accelerating its own scientific output, European leaders are facing mounting pressure to revitalize their domestic life-sciences ecosystem to ensure future prosperity and health security.
What Happened
The pharmaceutical sector, once a European stronghold, has experienced a steady erosion of its global market position. Following a period of dominance during the 1990s, Europe ceded its lead to the United States in the early 2000s. By 2024, China had also surpassed the European Union in the launch of new medical treatments.
Investment patterns reflect this decline, with the EU’s share of global research and development funding dropping significantly over the last two decades. Furthermore, there has been a marked decrease in the number of clinical trials hosted within European borders, signaling a shift in where the future of medicine is being defined.
Background
The pharmaceutical industry is now recognized as a vital pillar of European strategic autonomy and economic competitiveness. The COVID-19 pandemic served as a stark reminder of the risks associated with relying on external supply chains for essential medicine. Consequently, the ability to develop and manufacture treatments locally is no longer viewed merely as an economic pursuit, but as a fundamental requirement for national and regional security.
The competitive gap is further widened by the regulatory and fiscal environments abroad. The United States, which commands a larger segment of the global pharmaceutical market, has historically provided robust incentives for research. New American policies aimed at bolstering domestic manufacturing and attracting further investment are expected to heighten the pressure on European policymakers to respond with their own strategic enhancements.
Key Details
| Metric | Historical/Current Context |
|---|---|
| Research Leadership | Europe led in the 1990s, lost the lead to the U.S. in the 2000s, and to China by 2024. |
| Development Timeline | The creation of a new medicine typically requires a period of 10 to 15 years. |
| Spain’s Market Position | Fourth-largest pharmaceutical market in Europe and a leader in clinical trials. |
| Strategic Focus | Advanced therapies, AI-driven drug discovery, and personalized treatments. |
Impact
The migration of clinical trials and patent filings away from Europe represents a tangible loss of specialized knowledge and high-quality employment opportunities. This brain drain risks stalling the continent's ability to innovate in high-growth areas, such as genetic disease treatments and advanced oncology.
Spain serves as a primary example of the current paradox. Despite being a top-tier European market with high research activity, patients often face significant delays in accessing newly approved treatments. This disconnect between scientific excellence and patient access is a continent-wide challenge that threatens to undermine the societal value of medical research.
What Happens Next
The upcoming European Biotech Act is positioned as a potential turning point for the industry. If successfully implemented, the legislation aims to reduce administrative hurdles, improve access to venture capital, and establish regulatory sandboxes for advanced therapies.
Additionally, the European Health Data Area could prove decisive if it succeeds in fostering interoperability and public trust. These initiatives are intended to support the integration of artificial intelligence into drug discovery and clinical trial optimization. Ultimately, policymakers must prioritize the protection of intellectual property, ensure predictable regulatory frameworks, and modernize industrial policies to maintain Europe’s role as a global leader in health innovation.
Every clinical trial that moves away and every patent filed outside Europe mean a real loss of knowledge, skilled jobs and opportunities for Europeans.
Developing a medicine takes 10 to 15 years, which is why companies need predictable regulation, legal certainty and policies that recognize the value of innovation.
Policymakers must now act with urgency: protect and reward innovation, remove barriers to faster access, strengthen Europe’s industrial and research base, and make biomedical innovation a strategic priority.
Disclaimer: This article constitutes a political advertisement sponsored by EFPIA. The content relates to EU pharmaceutical and life-sciences policy, advocating for stronger incentives, faster patient access to treatments, and increased support for biomedical competitiveness.
